Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial

Feb.07.2024
Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial
Philippine newspaper Manila Standard calls for a reassessment of the country's e-cigarette law in an editorial.

The large Philippine newspaper Manila Standard recently published an editorial calling for a reassessment of the country's e-cigarette bill.


On July 25, 2022, the Republic Act No. 11900 was enacted in the Philippines with the aim of regulating the importation, sale, packaging, distribution, use, and promotion of "vaporized nicotine and non-nicotine products, as well as new tobacco products such as vape and heated tobacco products." However, in the past two years since its introduction, the law has lowered the age restriction for such products from 21 to 18 years old, lifted the ban on smoking and using heated tobacco products in public places, and allowed advertising and promotion of these products.


The law allows for the online sale of products with nicotine concentrations not exceeding 65 milligrams per milliliter (6.5%), and lowers the legal purchasing age from 21 to 18. This means that more young people will be able to use e-cigarettes as an alternative to smoking (the legal age to purchase cigarettes is 18).


The editorial argues that this law overlooks the fact that tobacco is the highest risk factor for causing deaths and disabilities in both smokers and non-smokers in 2019.


It is estimated that tobacco use was responsible for over 112,112 deaths, accounting for 27% of the total deaths in the Philippines that year.


According to researchers, 96,000 deaths (85%) are caused by smoking, while 22,000 deaths (19%) are caused by secondhand smoke. It is estimated that approximately 8 million people die prematurely every year due to cigarette smoke, which is a complex mixture of chemicals combined with aerosol particles or present in the gas phase. This has been a major health issue for several decades.


The report also noted that the main reasons why students use e-cigarettes include easy online access (32%), flavors (22%), and a perception that e-cigarettes are safer than traditional cigarettes (17%).


Editorial: The editorial asserts that e-cigarettes have not been around for a long time, and authorities are still uncertain about the long-term risks associated with their use. While the harm posed by vaping is considerably lesser than smoking, it cannot be deemed entirely harmless. This is where the problem lies. Therefore, the healthiest choice would be to abstain from smoking or vaping altogether.


The editorial also quotes health experts saying, "If someone uses e-cigarettes to quit smoking, their ultimate goal should be to eventually quit using e-cigarettes." The article further mentions that according to research, emerging data suggests a link between e-cigarettes and chronic lung diseases and asthma. Additionally, using both e-cigarettes and traditional cigarettes has also been associated with cardiovascular diseases.


In conclusion, there is not much difference between smoking and using e-cigarettes, as stated in the editorial. People generally believe that smoking is more harmful because the products are burned and smoke is inhaled into the lungs. However, research has shown that the damage caused by heating and inhaling solution vapor into the lungs is very similar to that of smoke. Based on this, the report calls for a reevaluation of the country's e-cigarette legislation.


The Manila Standard newspaper was established on February 11, 1987. It is controlled by the Romualdez political family, specifically the current Speaker of the House of Representatives, Ferdinand Martin Gomez Romualdez.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
RELX and UK e-liquid brand T-Juice have launched the Prime Pro × Red Astaire bundle in France, combining the RELX Prime Pro open-system pod device with T-Juice’s signature Red Astaire nicotine salt e-liquid. The collaboration retains the existing Prime Pro hardware platform while using an established flavor brand to create a complete open-system offering. The product appeared in French retail and distribution channels in August 2026 and represents a co-branded retail bundle rather than a new device launch.
Aug.27
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
BAT Rothmans says it previously considered exiting South Korea's vaping market because of competitive pressure from unregulated products, but is now reassessing conditions following changes to the country's nicotine regulatory framework. Vuse and other BAT vaping products remain available through existing distribution channels. The statement followed a South Korean media report that interpreted BAT's broader withdrawal from selected Vapour markets as a full exit from South Korea. Meanwhile, Philip Morris International launched VEEV inPRIME in the country in June and began expanding distribution to around 14,000 convenience stores and other retail channels in July. The contrasting moves highlight differing investment strategies as South Korea's regulated vaping market evolves.
Aug.14
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22